Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Study sponsor: Silence Therapeutics plc · SLN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-01-11Actual
Enrollment · participants180Actual
Source updated2025-07-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.